Literature DB >> 27725437

Acyl-glucuronide as a Possible Cause of Trovafloxacin-Induced Liver Toxicity: Induction of Chemokine (C-X-C Motif) Ligand 2 by Trovafloxacin Acyl-glucuronide.

Ryo Mitsugi1, Kyohei Sumida, Yoshiko Fujie, Robert H Tukey, Tomoo Itoh, Ryoichi Fujiwara.   

Abstract

Trovafloxacin is an antibiotic that was withdrawn from the market relatively soon after its release due to the risk of hepatotoxicity. Trovafloxacin is mainly metabolized to its acyl-glucuronide by uridine 5'-diphosphate (UDP)-glucuronosyltransferase (UGT) 1A1. In this study, we examined whether the acyl-glucuronide is involved in the development of hepatotoxicity. A UGT1A1-induced cell model was developed and the toxicity of trovafloxacin acyl-glucuronide was evaluated. The UGT1A1-induced cell model was developed by treating HepG2 cells with chrysin for 48 h. Chemokine (C-X-C motif) ligand 2, a cytokine involved in drug-induced liver injury, was uniquely induced by trovafloxacin in the UGT1A1-induced HepG2 cells. Induction of UGT1A1 resulted in a decrease in cell viability. An in vivo animal study further demonstrated the importance of UGT1A1 in the trovafloxacin-induced liver toxicity. Although the complete mechanism of trovafloxacin-induced liver injury is still unknown, trovafloxacin acyl-glucuronide can be involved in the development of toxic reactions in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27725437      PMCID: PMC5673480          DOI: 10.1248/bpb.b16-00195

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  45 in total

Review 1.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 2.  The small intestine as a xenobiotic-metabolizing organ.

Authors:  Laurence S Kaminsky; Qing-Yu Zhang
Journal:  Drug Metab Dispos       Date:  2003-12       Impact factor: 3.922

3.  Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin.

Authors:  Michael J Liguori; Mark G Anderson; Stanley Bukofzer; James McKim; Jeffrey F Pregenzer; Jacques Retief; Brian B Spear; Jeffrey F Waring
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

4.  Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus.

Authors:  M Ciotti; N Basu; M Brangi; I S Owens
Journal:  Biochem Biophys Res Commun       Date:  1999-06-24       Impact factor: 3.575

5.  Alteration of the function of the UDP-glucuronosyltransferase 1A subfamily by cytochrome P450 3A4: different susceptibility for UGT isoforms and UGT1A1/7 variants.

Authors:  Yuji Ishii; Hiroki Koba; Kousuke Kinoshita; Toshiya Oizaki; Yuki Iwamoto; Shuso Takeda; Yuu Miyauchi; Yoshio Nishimura; Natsuki Egoshi; Futoshi Taura; Satoshi Morimoto; Shin'ichi Ikushiro; Kiyoshi Nagata; Yasushi Yamazoe; Peter I Mackenzie; Hideyuki Yamada
Journal:  Drug Metab Dispos       Date:  2013-11-19       Impact factor: 3.922

6.  Expression of UDP-Glucuronosyltransferase 1 (UGT1) and Glucuronidation Activity toward Endogenous Substances in Humanized UGT1 Mouse Brain.

Authors:  Yuki Kutsuno; Rika Hirashima; Masaya Sakamoto; Hiroko Ushikubo; Hirofumi Michimae; Tomoo Itoh; Robert H Tukey; Ryoichi Fujiwara
Journal:  Drug Metab Dispos       Date:  2015-05-07       Impact factor: 3.922

7.  A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini.

Authors:  J K Ritter; F Chen; Y Y Sheen; H M Tran; S Kimura; M T Yeatman; I S Owens
Journal:  J Biol Chem       Date:  1992-02-15       Impact factor: 5.157

8.  Hepatocyte signaling through CXC chemokine receptor-2 is detrimental to liver recovery after ischemia/reperfusion in mice.

Authors:  Satoshi Kuboki; Thomas Shin; Nadine Huber; Thorsten Eismann; Elizabeth Galloway; Rebecca Schuster; John Blanchard; Michael J Edwards; Alex B Lentsch
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

9.  The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential.

Authors:  John O Miners; Peter I Mackenzie; Kathleen M Knights
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

10.  Expression of human solute carrier family transporters in skin: possible contributor to drug-induced skin disorders.

Authors:  Ryoichi Fujiwara; Saya Takenaka; Mitsuhiro Hashimoto; Tomoya Narawa; Tomoo Itoh
Journal:  Sci Rep       Date:  2014-06-11       Impact factor: 4.379

View more
  4 in total

1.  Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22).

Authors:  Sabrina Jones; Azure L Yarbrough; Amal Shoeib; John M Bush; William E Fantegrossi; Paul L Prather; Anna Radominska-Pandya; Ryoichi Fujiwara
Journal:  Xenobiotica       Date:  2019-03-20       Impact factor: 1.908

2.  Prediction of drug-induced liver injury using keratinocytes.

Authors:  Rika Hirashima; Tomoo Itoh; Robert H Tukey; Ryoichi Fujiwara
Journal:  J Appl Toxicol       Date:  2017-01-31       Impact factor: 3.446

Review 3.  Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans.

Authors:  Ryoichi Fujiwara; Emiko Yoda; Robert H Tukey
Journal:  Drug Metab Pharmacokinet       Date:  2017-10-07       Impact factor: 3.614

Review 4.  PXR-mediated idiosyncratic drug-induced liver injury: mechanistic insights and targeting approaches.

Authors:  Jingheng Wang; Monicah Bwayi; Rebecca R Florke Gee; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-06-16       Impact factor: 4.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.